Followers | 63 |
Posts | 8502 |
Boards Moderated | 0 |
Alias Born | 01/10/2014 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, December 04, 2019 11:56:22 AM
Excellent article.
One of the most exciting times for bioscience investors is during a positive regulatory binary, i.e. a drug approval. As I forecasted, Global Blood Therapeutics (GBT) gained FDA approval for its lead medicine, Oxbryta. Being the first of its kind, Oxbryta has a very strong chance of dominating an untamed market.
From a trading viewpoint, the stock usually but not always rallies after an approval. However, there are situations where the stock trades either sideways or lower. Regardless of the immediate or short-term event, a fundamentally strong company nearly always appreciates in the long haul. Either that or it'll get bought out to reward investors with a huge premium. In this article, I'll feature a fundamental update on GBT and provide my expectations for this intriguing growth equity.
In all, I maintain my buy recommendation on GBT with the four out of five stars rating. Riding the historic Oxbryta approval, GBT now has the best new medicine for SCD. Not only that Oxbryta has an excellent efficacy and safety profile, but it also is the only of its kind. As such, physicians are motivated to prescribe the drug when they know about it. That is to say when the marketing kicks in.
Now the SCD market is quite large, standing at approximately $3B without a dominant drug. As you see, Oxbryta is making its entry into this niche as a gamed "Apex predator." To be realistic, there are still crucial factors that can deter successful commercialization. While you don't have to agree with me, you should weigh the negatives and positives to gauge the long-term prospect of GBT.
Last but not least, two surprise catalysts can occur going forward. One is that GBT suddenly announced a marketing partner. Another possibility is a buyout. Either one would be a surprise present for the holiday.
Here is the entire article:
https://seekingalpha.com/article/4310396-global-blood-therapeutics-oxbryta-is-aimed-for-success
Statements made are only my opinion. Do your own DD in order to make your Investment decisions.
Recent GBT News
- GROUPE BMTC INC. ANNONCE L'ACQUISITION D'UN CENTRE DE DISTRIBUTION À TERREBONNE AFIN DE GÉNÉRER DES REVENUS LOCATIFS À LONG TERME • PR Newswire (Canada) • 04/15/2024 11:30:00 PM
- BMTC GROUP INC. ANNOUNCES THE ACQUISITION OF A DISTRIBUTION CENTER TO GENERATE LONG-TERM RENTAL INCOME • PR Newswire (Canada) • 04/15/2024 11:30:00 PM
- GROUPE BMTC INC. ANNONCE LE RENOUVELLEMENT DE SON OFFRE DE RACHAT DANS LE COURS NORMAL DES ACTIVITÉS VISANT SES ACTIONS ORDINAIRES • PR Newswire (Canada) • 04/10/2024 11:30:00 PM
- BMTC GROUP INC. ANNOUNCES THE RENEWAL OF ITS NORMAL COURSE ISSUER BID TO ACQUIRE COMMON SHARES • PR Newswire (Canada) • 04/10/2024 11:30:00 PM
- GROUPE BMTC INC. ANNONCE SES RÉSULTATS FINANCIERS POUR LA PÉRIODE DE NEUF MOIS TERMINÉE LE 31 OCTOBRE 2023 • PR Newswire (Canada) • 12/12/2023 12:30:00 AM
- BMTC GROUP INC. ANNOUNCES FINANCIAL RESULTS FOR THE NINE MONTH PERIOD ENDED OCTOBER 31st, 2023 • PR Newswire (Canada) • 12/12/2023 12:30:00 AM
- BMTC GROUP INC. ANNOUNCES FINANCIAL RESULTS FOR THE SEMESTER ENDED JULY 31st, 2023 • PR Newswire (Canada) • 09/07/2023 11:30:00 PM
- GROUPE BMTC INC. ANNONCE SES RÉSULTATS FINANCIERS POUR LE SEMESTRE TERMINÉ LE 31 JUILLET 2023 • PR Newswire (Canada) • 09/07/2023 11:30:00 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM